Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Refractory Dermatomyositis
NCT04946669Phase 1Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in dermatomyositis (DM), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: IMACS score improved at 12 weeks. Status: unknown.
02
Drugs
abatacept
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04946669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946669.